News from the FDA/CDC
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
News from the FDA/CDC
FDA approves abatacept for pediatric patients with psoriatic arthritis
As many as 5% of pediatric patients with juvenile idiopathic arthritis are estimated to have juvenile PsA.
News from the FDA/CDC
FDA warns of hidden ingredients in arthritis, pain products
“I don’t know if this was intentional, but it seems suspicious that a product marketed to reduce joint pain and inflammation contains prescription...
News from the FDA/CDC
Approximately 20% of U.S. adults are diagnosed with arthritis
New data show disproportionate arthritis prevalence among women, veterans, non-Hispanic White individuals, and those aged 45 years and older.
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...
News from the FDA/CDC
FDA approves first tocilizumab biosimilar
Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.
Latest News
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
The cosmetic products include makeup products, nail polishes, shaving creams, other grooming products, perfumes, face and body cleansers, hair...
News from the FDA/CDC
FDA approves canakinumab for gout flares
Canakinumab is the first biologic in the U.S. approved for treating gout flares.
Latest News
Despite recent uptick in cases, leprosy is very rare, expert says
Over the past several years, 150-250 cases of leprosy have been reported each year.
News from the FDA/CDC
FDA approves first over-the-counter birth control pill
The product, OPill, is expected to be available early in 2024.